Pain Expert Edward Mariano, MD, MAS, Highlights Journavx and the Newly-Approved Nonopioid's Mechanism of Action

Edward R Mariano, MD, MAS, is a professor and vice chair in the department of anesthesiology, perioperative and pain medicine at Stanford University School of Medicine in Stanford, CA. He spoke with Patient Care when Journavx (suzetrigine), a novel highly selective voltage-gated sodium channel (NaV1.8) inhibitor, received FDA approval for management of moderate-to-sever acute pain. Journavx, developed by Vertex Pharmaceuticals, is an oral first-in-class analgesic and represents the first new approach to pain management in more than 20 years.

In the short video above, Mariano discusses the novel mechanism of action, the role this first nonopioid will play as a novel tool for acute pain management, and the importance of its favorable safety profile.

Edward R Mariano, MD, MAS, is a professor and vice chair in the department of anesthesiology, perioperative and pain medicine at Stanford University School of Medicine in Stanford, CA and chief of anesthesiology and perioperative care service at the Veterans Affairs Palo Alto Health Care System. Mariano pioneered the use of continuous peripheral nerve blocks for individuals having same-day surgery. He has worked on key national health care initiatives in the US including accreditation of regional anesthesiology and acute pain medicine fellowships, pain management guidelines, and hospital-based standards.